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Skeletal muscle uses calcium as a second messenger to respond and adapt to environmental stimuli. Elevations in intracellular
calcium levels activate calcineurin, a serine/threonine phosphatase, resulting in the expression of a set of genes involved in
the maintenance, growth, and remodeling of skeletal muscle. In this review, we discuss the eﬀects of calcineurin activity on
hypertrophy, regeneration, and disorders of skeletal muscle. Calcineurin is a potent regulator of muscle remodeling, enhancing
the diﬀerentiation through upregulation of myogenin or MEF2A and downregulation of the Id1 family and myostatin. Foxo may
also be a downstream candidate for a calcineurin signaling molecule during muscle regeneration. The strategy of controlling the
amount of calcineurin may be eﬀective for the treatment of muscular disorders such as DMD, UCMD, and LGMD. Activation of
calcineurin produces muscular hypertrophy of the slow-twitch soleus muscle but not fast-twitch muscles.
1.Introduction
Calcium serves as a second messenger in signal transduction
pathways, using spatiotemporal patterns of intracellular
calcium to generate oscillatory changes in calcium concen-
trations. It is well established that the elevations in intra-
cellular calcium levels in skeletal muscle that are essential
for contractile activity also give rise to muscle-speciﬁc gene
expression through downstream transcriptional pathways
[1, 2]. Changes in intracellular Ca2+ concentrations regulate
the physiological activities of calmodulin. Calmodulin is a
multifunctional signal transducer that undergoes conforma-
tional changes before activating a wide range of binding
substrates, mainly downstream phosphatases (calcineurin)
and kinases (CaMKs) [3]. The serine/threonine phosphatase
calcineurin plays a major role in a variety of physiological
and pathological processes, including immune responses,
neuronal plasticity, and cardiac development and hyper-
trophy [4]. For example, transgenic mice overexpressing
calcineurinA developed a profound hypertrophic responses
and heart failure that mimicked human heart disease [5].
Bueno et al. [6] demonstrated that calcineurin Aβ null mice
showed a reduced basal heart size. In addition, the absence
of NFATc2 (the nuclear factor of activated T cells c2) has
been shown to inhibit pathological (biomechanical stress)
but not physiological (voluntary exercise training) cardiac
enlargement [7]. Although the downstream pathway of
calcineurin is not completely clear [8], calcineurin signaling
seems to play an important role in cardiac muscle. Many
excellent reviews [8, 9] have indicated a central role for
calcineurin signaling in determining ﬁber types and myosin
heavy chain (MHC) (IIB → IID → IIA → I ) .H o w e v e r ,f e w
systematic and descriptive reviews have dealt with the role of
calcineurin in regulating the hypertrophy and regeneration
of skeletal muscle in mature mammals. This review aims to
outline the functional role of calcineurin in the hypertrophy
and regeneration of skeletal muscle. In addition, it discusses
the present situation and future therapeutic applications
for modulating calcineurin levels to alleviate muscular
disorders.2 Journal of Biomedicine and Biotechnology
2. Structureof Calcineurin
Calcineurin enzymatic activity requires a catalytic subunit
(CnA, 59 to 62kDa) and a calcium-binding regulatory
subunit (CnB, 19kDa), which comprise several isoforms
coded by diﬀerent genes or generated by alternative splicing.
TheCnAsubunitincludesdomainsforcatalyticactivity,CnB
interaction, and calmodulin-binding. A C-terminal autoin-
hibitory domain, which blocks the catalytic site, is removed
inresponsetoanincreaseincalcium.Threecalcineuringenes
havebeendescribed;cnAαandCnAβexpressedubiquitously,
and CnAγ restricted to brain and testis. Two CnAβ iso-
forms, CnAβ1 and CnAβ2, which diﬀer in their C-terminal
domain, are encoded by alternatively spliced transcripts
[10]. The typical autoinhibitory domain present in CnAβ2
and other calcineurin isoforms is absent from CnAβ1, in
which an unrelated C-terminal domain is generated by the
translation of intronic sequences [11]. This novel domain is
preserved in CnAβ1 orthologues from diﬀerent species [11],
especially in higher vertebrates, suggesting an evolutionarily
conserved role for this calcineurin variant. When activated
by Ca2+-calmodulin binding, calcineurin aﬀectsgene expres-
sion by dephosphorylating speciﬁc substrates, including
the four calcineurin-dependent members of NFAT gene
family, NFATc1, NFATc2, NFATc3, and NFATc4. Following
dephosphorylation, NFAT translocates from the cytoplasm
to the nucleus and activates target genes in cooperation with
other transcription factors [12]. Calcineurin activity and
the ability to activate NFAT are directly antagonized by the
immunosuppressiveagentsFK506andcyclosporineA(CsA)
through complexes with cyclophillins and FK506-binding
proteins, respectively [13, 14], or by endogeneous protein
inhibitors, such as cain (also known as cabin-1) and MCIP-
1 (myocyte-enriched calcineurin interacting protein 1), the
latter being particularly abundant in slow-twitch muscle but
notdetectableinfast-twitchglycolyticmuscles[15,16].More
recently, reporter assays using cultured myoblasts indicated
that the transcriptional activation of NFAT by calcineurin
was also inhibited by calsarcin-2 [17].
3. Muscle Regeneration
Skeletal muscle satellite cells are generally in a quiescent
state in adult muscle, but when minor damage or injury
occurs, signals are generated within the muscle that activate
these satellite cells, stimulating them to migrate to the site
of an injury where they proliferate, diﬀerentiate, and fuse
with the damaged ﬁbers or form new ﬁbers [18, 19]. Studies
in vitro have documented many factors, primarily protein
growth factors, which can modulate satellite cell activity
[18, 19]. In particular, insulin-like growth factor I (IGF-I),
whose expression is known to be upregulated in regenerating
muscleinvivo[20],positivelyregulatedtheproliferationand
diﬀerentiationofsatellitecells/myoblastsinvitroviadiﬀerent
pathways. Calcineurin is a major candidate for a component
in the pathway downstream of IGF-I as well as Akt. In
fact, the inhibition of calcineurin completely blocked the
growth of myotubes on treatment with IGF-I in vitro [21].
L o c a le x p r e s s i o no fI G F - Ii nm u s c l ep r o t e c t e db o t hm o t o r
neurons and innervating muscle ﬁbers in a mouse model
of amyotrophic lateral sclerosis (the SOD1G93A transgenic
mouse) possibly due to the enhancement of CnAβ1[ 22].
Since activated calcineurin promotes the transcription and
activation of myocyte enhance factor 2(MEF2), myogenin,
and MyoD [23–25], calcineurin seems to control satellite
cell diﬀerentiation and myoﬁber growth and maturation,
all of which are involved in muscle regeneration. In fact,
our previous Western blot analysis [26] showed a long-
term (1–14 days post bupivacaine injection) increase in the
amount of calcineurin protein in the regenerating muscle of
adultrats.Immunoﬂuorescencemicroscopyrevealedmarked
immunolabeling of calcineurin in many myoblasts and
myotubes that expressed MyoD and myogenin at an active
diﬀerentiation phase (4–6 days post injection). In addition,
our biochemical approach demonstrated that the amount of
calcineurin coprecipitating with NFATc1 and GATA-2 and
NFATc1 coprecipitating with GATA-2 gradually increased
in the regenerating muscle. Furthermore, we showed that
the inhibition of calcineurin by CsA induced extensive
inﬂammation, marked ﬁber atrophy, the appearance of
immature myotubes, and calciﬁcation in the regenerating
muscle compared with placebo-treated mice [26]. Several
other studies indicated such defects in skeletal muscle
when calcineurin was inhibited [27, 28], whereas transgenic
activation of calcineurin is known to markedly promote the
remodeling of muscle ﬁbers after damage [11, 29].
Myostatin is a member of the transforming growth
factor-β (TGF-β) family that negatively regulates skeletal
muscle growth, with its inhibition shown to enhance muscle
size. Mice, which are null for (knock-out) or display
inactivating mutations of myostatin, exhibit obvious skeletal
muscle hyperplasia and hypertrophy [30, 31]. Recent evi-
dence [32–34] has also identiﬁed myostatin as well as Id1
[22], Id3 [22], and Egr-1 [25] as a possible downstream neg-
ative hypertrophic eﬀector target of the calcineurin-NFAT
pathway. In addition, using a pharmacological approach
(intraperitoneal CsA treatment), our recent study [35]
demonstratedthattheinhibitionofcalcineurinenhancedthe
expression of myostatin and Smad3 mRNA in regeneration-
defective TA muscle after an injection of bupivacaine. An
increase in myostatin levels is closely linked with muscle
atrophy after unloading in mice and humans [36–38]a n d
with severe muscle wasting in HIV patients [39]. Myostatin
has been shown to interact with Smad2 and Smad3 [40,
41], and the activation of the myostatin pathway inhibits
myogenicdiﬀerentiationthroughadownregulationofMyoD
expression [40, 41]. The possibility that myostatin is a
downstream mediator of calcineurin signaling has been
indicatedbyrecentexperimentswithtwodiﬀerenttransgenic
mice [42]. Muthuri et al. [42] found that myostatin mRNA
levels in skeletal muscle were signiﬁcantly lower in mice
expressing high levels of calcineurin and signiﬁcantly higher
in mice displaying inhibited calcineurin signals. Moreover,
levels of calcineurin mRNA were higher in null myostatin
transgenic mice than wild-type mice [42]. On the other
hand, using MCK-CnAα transgenic mice, Stupka et al. [29]
demonstrated that calcineurin activates two diﬀerentiation-
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regeneration. Indeed, calcineurins pharmacological inhibi-
tion caused a decline in the transcription and activation
of MEF2, myogenin and MyoD during myogenic diﬀeren-
tiation in vitro [23–25]. However, the notion that muscle
regeneration is promoted by a myogenic transgene with
CnAα is controvertial [11, 29] .Am o r er e c e n ts t u d yu s i n g
a similar mouse model found that transgenic expression of
CnAα excessly stimulated the inﬂammatory response after
muscle damage and prevented prompt muscle regeneration
[11].
The induction of MAFbx/Atrogin-1 expression by Foxo
has been shown to inhibit calcineurin activity [43, 44].
More recently, the calcineurin variant CnAβ1w a ss u g g e s t e d
to block the nuclear localization of Foxo protein and the
expressionofseveralFoxo-targetedgenes(MuRF1,Gadd45a,
Pmaip1, and atrogin) in C2C12 myoblasts [11]. In addition,
transgenic upregulation of CnAβ1 expression promoted the
remodeling of cardiotoxin-treated damaged muscle ﬁbers
[11]. Foxo factors play a crucial role in skeletal muscle
atrophy through the induction of MAFbx/Atrogin-1 and
MuRF1 [45, 46]. Interaction between CnAβ1 and Foxo in
muscle regeneration is an attractive notion, although it has
not been demonstrated in adult skeletal muscle in vivo.
4. Muscle Hypertrophy
The major extracellular mediator of skeletal muscle hyper-
trophy is thought to be IGF-I which binds to its receptor to
initiate a cascade of signaling pathways via phosphoinosi-
tide 3-kinase (PI3-K/Akt/mammalian target of rapamycin
(mTOR)) [47–49]. However, several lines of evidence sug-
gest that IGF-I also mediates hypertrophy through cal-
cineurin/NFAT signaling pathways. Overexpression of IGF-I
in murine C2C12 myoblasts [21]a n dr a tL 6 M L Cc e l l s[ 50]
induced hypertrophy of myotubes, which was abolished by
treating the cells with CsA. Dunn et al. [51] proposed that
calcineurin signaling regulates the hypertrophy of muscle
ﬁber in mature rats. They concluded that the enlargement
of ﬁbers in the plantaris muscle after mechanical overloading
was completely blocked at both 2 and 4 weeks post surgery
by subcutaneous treatment with CsA at 25mg/Kg twice per
day. However, several lines of evidence exclude a functional
role for calcineurin in the hypertrophy of muscle ﬁber in
vivo [52–55]. For example, diﬀerent to the positive eﬀect
of rapamycin, the calcineurin inhibitors CsA and FK506 for
up to 30 days did not block the hypertrophy of plantaris
muscle that followed surgical removal of the soleus, medial,
and lateral gastrocnemius muscles in the rat [53]. Consistent
with these ﬁndings, others have demonstrated that even a
tenfold increase in the expression of activated calcineurin
in transgenic mice did not induce muscle hypertrophy [53]
in spite of an increase in the proportion of slow muscle
ﬁbers due to the inﬂuence of CnA. In addition, Parsons et
al. [54] indicated that neither CnAα nor CnAβ null mice
showed any growth-related alterations in skeletal muscle,
and ﬁber size or number was not altered in glycolytic/fast
muscle types (tibialis anterior, gastrocnemius, quadriceps,
etc). Furthermore, no change in the size of several fast-type
muscles has been observed in mice with a transgenic upreg-
ulation of calcineurin [56], although a transgenic mouse
with a constitutively active form of Akt exhibited rapid and
signiﬁcant hypertrophy of fast-type muscles [57]. However,
Talmadge et al. [56] also demonstrated that overexpression
ofcalcineurininducedmarkedhypertrophyofslow-andfast-
twitchﬁbersoftheslow-typesoleusmuscle.Inaddition,ﬁber
size in the soleus muscle was markedly reduced by a null
mutation of CnAβ diﬀerent to CnAα [54]. Muscle-speciﬁc
overexpression of MCIP1, an inhibitor of calcineurin, using
the Flox-On approach resulted in a marked reduction (about
30%) in cross-sectional area of the soleus muscle [58].
Moreover, our recent study [59] using ICR mice did not
detect any apparent hypertrophy of ﬁbers in the soleus
muscle after mechanical overloading on treatment with CsA.
Other researchers also suggest growth-retarded eﬀects in
the soleus muscle caused by calcineurins inhibition during
recovery from hindlimb unloading [60–62]. These lines of
evidence seem to indicate a selective inﬂuence of calcineurin
or Akt on the size of antigravity/slow-type soleus and fast-
type muscles, respectively. Table 1 shows an overview of the
eﬀect of calcineurin activation or inhibition on ﬁber growth
(hypertrophy) of skeletal muscle in vivo.
Although calcineurin activity appears critical to mediat-
ing the hypertrophy of slow-type muscle, the downstream
eﬀector genes or targets in this process have yet to be clearly
deﬁned. Various downstream mediators of calcineuirin-
dependent signaling have been proposed [34], including
NFAT and MEF2 proteins as well as GATA transcription
factors. These factors are known to costimulate the tran-
scriptional response of certain hypertrophic marker genes in
the heart [63, 64]a n da ﬀect IGF-I-related growth of skeletal
myocytes in vitro [50]. GATA-2 expression is upregulated
[65] and NFAT more extensively dephosphorylated [63]
in hypertrophying fast-type plantaris muscle in vivo. In
addition, mice with targeted inactivation of NFATc2 or
NFATc3 exhibited reduced muscle size as well as ﬁber type
abnormalities [66] or defects in muscle formation [67],
respectively. Cultured C2C12 murine myoblasts expressing
activated calcineurin showed increased enzymatic activity
in association with NFATc3’s nuclear translocation during
the initiation of myogenic diﬀerentiation [23]. Given these
ﬁndings, NFAT and GATA seem to play an important role
in the normal growth and hypertrophy of skeletal muscle.
Therefore, NFAT-GATA complexes may be mediators of
calcineurin signaling during the hypertrophic process in
soleus muscle. In contrast, a more recent study in our
laboratory [58] suggested that MEF2C, not MEF2D or
myogenin, regulates the hypertrophic process in slow-twitch
soleus muscle subjected to mechanical overloading (MOV).
Hypertrophy-defect soleus muscle after mechanical over-
loadingby calcineurin inhibition contained less MEF2C pro-
tein than a placebo-treated control. In addition, this growth-
failed soleus muscle showed less extensive immunoreactivity
to MEF2C in the subsarcolemmal region in a group of
myotubes and/or myoﬁbers during an active-diﬀerentiation
period(4dayspostsurgery)[59].Tworecentﬁndings[68,69]
clearly showed that MEF2C is required for thick ﬁlaments
to form in nascent muscle ﬁbers and for the integrity of4 Journal of Biomedicine and Biotechnology
Table 1: Eﬀect of calcineurin activation or inhibition on ﬁber growth (hypertrophy) of skeletal muscle in vivo.
References Species Experimental system Modulating method of
calcineurin activity Outcomes
Dunn et al.
1999 [51] Mouse Mechanical
overloading
Pharmacological inhibition
for 4 weeks (CsA; 25mg/Kg
twice daily)
Inhibition of ﬁber
hypertrophy of the plantaris
muscle
Bodine et al.
2001 [53] Mouse Mechanical
overloading
Pharmacological inhibition
f o r3 0d a y s( C s A ;1 5m g / K g
once daily)
No inhibition of ﬁber
hypertrophy of the plantaris
muscle
Sakuma et al.
2008 [59] Mouse Mechanical
overloading
Pharmacological inhibition
for 2 weeks (CsA; 25mg/Kg
once daily)
Inhibition of ﬁber
hypertrophy of the soleus
muscle
Parsons et al.
2003 [54] Mouse Gene-knock out (complete
inactivation of cna α or cna β)
Slow-twitch soleus muscle;
hypertrophy (cna α KO),
atrophy (cna β KO),
Several fast-twitch muscles
(gastrocnemius, tibialis
anterior, triceps brachii); no
change (both cna α and cna β
KO)
Talmadge et
al. 2004 [56] Mouse
Transgenic manipulation
(high-level expression of a
constitutively active form of
calcineurin)
Slow-twitch soleus muscle;
marked hypertrophy
Several fast-twitch muscles
(extensor digitorum longus,
tibialis anterior, plantaris); no
change
Oh et al. 2006
[58] Mouse
(Transgenic manipulation
(Flox-On approach),
upregulation of calcineurin
inhibitor (MCIP1))
Atrophy of the soleus muscle
Mitchell et al.
2002 [60] Mouse
Reloading after
hindlimb
suspension
Pharmacological inhibition
for 2 weeks (CsA; 12.5, 25,
and 50mg/Kg once daily)
Inhibition of ﬁber growth
(recovery) of both the soleus
(25 and 50mg/Kg) and
plantaris (12.5, 25, and
50mg/Kg) muscles
Miyazaki et
al. 2006 [61] Mouse
Reloading after
hindlimb
suspension
Pharmacological inhibition
for 4 weeks (FK506;
3–5mg/Kg once daily)
Inhibition of ﬁber growth
(recovery) of the soleus
muscle
Oishi et al.
2008 [62] Rat
Reloading after
hindlimb
suspension
Pharmacological inhibition
for 2 weeks (CsA; 25mg/Kg
twice daily)
Inhibition of ﬁber growth
(recovery) of the soleus
muscle
the sarcomere and M-line during postnatal muscle growth,
by directly regulating several muscle structural genes such
as the genes for myomesin, MHC, and myosin light chain.
Further study will be required to identify downstream
modulators of calcineurin signaling during hypertrophy of
slow-twitch soleus muscle. Figure 1 provides an overview of
molecular pathway of calcineurin to regulate hypertrophy
and regeneration of skeletal muscle.
5. The Ameliorating Role of Calcineurinin
MuscularDisorders
Calcineurin signaling is considered to regulate the degener-
ative symptoms of various muscular disorders [74–84]. In
animal models, pharmacological inhibition of calcineurin
in regenerating muscles of young mdx dystrophic mice,
a model of DMD, severely compromised muscle structure
and function [76]. Moreover, transgenic mice overexpressing
the activated form of CnA have been used to determine
whether signaling through CnA improves the dystrophic
pathology due to alterations in the expression of utrophin
A, a therapeutically relevant protein that can compensate
for the lack of dystrophin, and improved muscle membrane
integrity [75]. Breeding CnA transgenic mice with mdx
counterparts led to oﬀspring (mdx-CnA) with both genes
altered in their skeletal muscle, but displaying a marked
improvement in the dystrophic phenotype. Muscles from
transgenic mdx-CnA mice showed improvements in various
markers of muscle damage, including a decrease in central
nucleation (indicating denervation or ﬁber regeneration),
a decrease of variation in ﬁber size, a decrease in the
intracellular presence of immunoglobulin M (a marker ofJournal of Biomedicine and Biotechnology 5
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Figure 1: Schematic diagram of calcineurin signaling to regulate hypertrophy and regeneration of skeletal muscle. Mechanical loading of
skeletal muscle increase intracellular Ca2+ levels via the inﬂux (L-type Ca2+ channel) of Ca2+ from the extracellular space and its eﬄux from
thesarcoplasmicreticulum.ThedamageofmuscleﬁbermembraneaftertreatmentwithmyotoxinalsoelicitsanincreaseinintracellularCa2+
levels via the inﬂux of Ca2+ from the extracellular space. Binding of the Ca2+/CaM complex to the calcineurin regulatory subunit leaded to its
activation. Activated calcineurin dephosphorylates NFATc1 [26, 65, 70], NFATc3 [23], MEF2C [59], and MEF2A [29, 70] resulting in their
translocation from the cytoplasm to the nucleus. These transcription factors induce the expression of hypertrophic and/or remodeling genes
such as Dev MHC [29], α-actin, IGF-I [71], myogenin [25], and IL-6 [72]. In addition, activated calcineurin inhibits the functional role of
Egr-1 [25]a n dm y o s t a t i n[ 32–34]. Mechanical overloading upregulates gene expression of IGF-I. IGF-I modulates calcineurin signaling via
increasing intracellular Ca2+ levels [25] and activating GATA-2 [50, 73]. MCIP1 [58] and calsarcin-2 [17] are potent inhibitors of calcineurin
signaling. MEF2A: Myocyte enhancer factor 2A; NFATc1: nuclear factor of activated T cells c1; MCIP1: Modulatory calcineurin-interacting
protein 1; IRS-1: Insulin receptor substrate-1; PI3-K: Phosphatidylinositol 3-kinase; CaM: Calmodulin; Dev MHC: Developmental myosin
heavy chain; IL-6: Interleukin-6.
sarcolemmal integrity), a decrease in the uptake of Evans
blue dye by muscle ﬁbers in vivo (indicating sarcolemmal
microdamage), and a decrease in numbers of inﬁltrat-
ing immune cells revealed by Mac-1 antibody staining
(a marker of an inﬂammatory response) [75]. Thus, an
attenuation of the muscle pathology-associated dystrophin
deﬁciency is observed when utrophin A is upregulated via
activation of CnA-NFAT signaling. In fact, Chakkalakal
et al. [74] showed that calcineurin/NFATc1 signaling as
well as peroxisome proliferator γ co-activator-1α (PGC-
1α)/GA-binding protein (GABPα)[ 77] can stimulate the
transcriptional activity of utrophin A. Subsequent similar
crossbreeding experiments by others [81, 83], leading to
mdx-CnA mice with potentiated CnA-NFAT activation,
showed related improvements in the contractile function
and attenuation of contractile-induced injury in muscles
from these animals comparted with mdx counterparts.
On the other hand, transgenic upregulation of the CaM-
binding protein (CaMBP), a small peptide inhibitor for
calmodulin, exacerbated the dystrophic phenotype in mdx
mouse muscle. mdx/CaMBP mice revealed an impairment
of both the Ca2+/CaM-regulated enzyme calcineurin and a
Ca2+/calmodulin-dependent kinase [78] .T h e s em i c ee x h i b -
ited signiﬁcant reductions in utrophin A attributable to
the marked decrease in nuclear accumulated NFATc1 and
MEF2C and in CABPα mRNA expression. In contrast,
pharmacological and genetic inhibition of calcineurin sig-
naling was suggested to be eﬀective in a mouse model and
in patients with several other muscular disorders such as
limb-girdle muscular dystrophy (LGMD), Ullrich congenital
muscular dystrophy (UCMD), and collagen VI myopathies
[81, 82, 84]. For example, in an open pilot trial, oral CsA
treatment for 1 month markedly ameliorated mitochondrial
dysfunction and reduced the frequency of apoptotic nuclei6 Journal of Biomedicine and Biotechnology
in muscle ﬁbers in patients with collagen VI myopathies
[84]. In addition, genetic deletion of the loxP-targeted
calcineurin B1 or CnAβ gene resulted in enlarged muscle
ﬁbers and decreases in the frequency of centrally nucleated
ﬁbers and of ﬁbrosis, and in the amount of hydroxyproline
in scgd−/− mice [82]. These ﬁndings clearly showed that
inhibition of calcineurin signaling reduced skeletal muscle
degeneration and the histopathology of LGMD. Since the
therapeutic eﬀectiveness of the pharmacological attenuation
or activation of calcineurin signaling diﬀers entirely among
muscular disorders, careful attention should be paid to this
application.
6. Conclusions
This review summarised and highlighted current under-
standing of the role of calcineurin in the regulation of
hypertrophy, regeneration, and disorders of skeletal muscle.
Although several lines of evidence exclude a functional role
for calcineurin in the hypertrophy of muscle ﬁber in vivo,
recent ﬁndings have suggested that the hypertrophy of slow-
twitch soleus muscle is regulated by calcineurin signaling. A
possible downstream modulator of the calcineurin pathway
during muscle regeneration may be MEF2A, myostatin, or
Foxo. The strategy of controlling the amount of calcineurin
may be eﬀective in the future treatment of muscular
disorders.
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